Results 61 to 70 of about 44,133 (142)

Impact of finasteride on modulating the risk and clinical outcomes of bladder cancer: insights from a comprehensive meta-analysis

Frontiers in Pharmacology
PurposeNumerous prior analyses have highlighted a potential link between androgen suppression therapy (AST) and bladder cancer (BCa). However, there is a notable gap in research specifically examining the influence of finasteride on BCa risk and clinical
Ailing Yu, Ailing Yu, Ailing Yu, Ailing Yu, Ailing Yu, Zian Bai, Zian Bai, Zian Bai, Zian Bai, Yijie Wang, Yijie Wang, Yijie Wang, Yijie Wang, Zhen Luo, Zhen Luo, Zhen Luo, Zhen Luo, Xiaochen Du, Mengxin Chen, Shuang Wen, Honglong Wang, Xiaoying Yuan, Chunyu Yang, Shanshan Bai, Bo Fan, Bo Fan, Bo Fan, Bo Fan   +27 more
doaj   +1 more source

5-Alpha Reductase Inhibitors and Prostate Cancer Mortality among Men with Regular Access to Screening and Health Care. [PDF]

Cancer Epidemiol Biomarkers Prev, 2022
Vaselkiv JB, Ceraolo C, Wilson KM, Pernar CH, Rencsok EM, Stopsack KH, Grob ST, Plym A, Giovannucci EL, Olumi AF, Kibel AS, Preston MA, Mucci LA.   +12 more
europepmc   +1 more source

5-Alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia. [PDF]

J Pathol, 2022
Joseph DB, Henry GH, Malewska A, Reese JC, Mauck RJ, Gahan JC, Hutchinson RC, Mohler JL, Roehrborn CG, Strand DW.   +9 more
europepmc   +1 more source

Efficacy and safety of oral finasteride versus dutasteride in moderate-to-severe androgenetic alopecia in males based on trichoscopic and laboratory findings: a clinical comparison in Iran

Journal of Dermatological Treatment
Background Androgenetic alopecia (AGA) is the most common type of hair loss in men. Finasteride and dutasteride are oral 5-alpha-reductase inhibitors. This study compared their efficacy and safety in Iranian men with moderate to severe AGA.Methods This ...
Nazila Poostiyan, Zahra Nikyar, Reza Makhmali, Mohsen Hosseini, Zabihollah Shahmoradi   +4 more
doaj   +1 more source

5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data. [PDF]

World J Urol, 2023
Del Giudice F, Belladelli F, Glover F, Basran S, Li S, Mulloy E, Pradere B, Soria F, Krajewski W, Nair R, Muncey W, Seranio N, Eisenberg ML.   +12 more
europepmc   +1 more source

The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs). [PDF]

Clin Epidemiol, 2021
Ayodele O, Cabral HJ, McManus D, Jick S.
europepmc   +1 more source

Do 5-alpha reductase inhibitors decrease the risk of recurrent gross hematuria in patients who have had a transurethral prostatectomy? [PDF]

Can Urol Assoc J, 2021
Welk B, Reid J, Ordon M, Campbell J, Dixon S.   +4 more
europepmc   +1 more source

Modulating testosterone pathway: a new strategy to tackle male skin aging?

Clinical Interventions in Aging, 2012
Philippe Bernard1, Thomas Scior2, Quoc Tuan Do11Greenpharma SAS, Orléans, France; 2Pharmacy Department, Benemerita Universidad Autonoma de Puebla, Puebla, MexicoAbstract: In men, the level of testosterone decreases with age. At the skin level, the
Bernard P, Scior T, Do QT
doaj  

Frontal fibrosing alopecia: efficacy of treatment modalities

International Journal of Women's Health, 2019
A Caresse Gamret,1 V Sumanth Potluri,1 Karthik Krishnamurthy,2 Raymond M Fertig31Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA; 2Division of Dermatology, Orange Park Medical Center, Orange ...
Gamret AC, Potluri VS, Krishnamurthy K, Fertig RM   +3 more
doaj  

5α-Reductase Inhibitors and Risk of Kidney and Bladder Cancers in Men with Benign Prostatic Hyperplasia: A Population-Based Cohort Study. [PDF]

Cancer Epidemiol Biomarkers Prev, 2023
Doherty N, Cardwell CR, Murchie P, Hill C, Azoulay L, Hicks B.   +5 more
europepmc   +1 more source